Urban wild meat consumption and trade in Central Amazonia

The switch from hunting wild meat for home consumption to supplying more lucrative city marketsin Amazonia can adversely affect some game species. Despite this, information on the amounts of wild meateaten in Amazonian cities is still limited. We estimated wild meat consumption rates in 5 cities in the State ofAmazonas in Brazil through 1046 door-to-door household interviews conducted from 2004 to 2012. With thesedata, we modeled the relationship between wild meat use and a selection of socioeconomic indices. We thenscaled up our model to determine the amounts of wild meat likely to be consumed annually in the 62 urbancenters in central Amazonia. A total of 80.3% of all interviewees reported consuming wild meat during an averageof 29.3 (CI 11.6) days per year. Most wild meat was reported as bought in local markets (80.1%) or hunted by afamily member (14.9%). Twenty-one taxa were cited as consumed, mostly mammals (71.6%), followed by reptiles(23.2%) and then birds (5.2%). The declared frequency of wild meat consumption was positively correlated withthe proportion of rural population as well as with the per capita gross domestic product of the municipality(administrative divisions) where the cities were seated. We estimated that as much as 10,691 t of wild meat mightbe consumed annually in the 62 urban centers within central Amazonia, the equivalent of 6.49 kg per person peryear. In monetary terms, this amounts to US$21.72 per person per year or US$35.1 million overall, the latter figureis comparable to fish and timber production in the region. Given this magnitude of wild meat trade in centralAmazonia, it is fundamental to integrate this activity into the formal economy and actively develop policies thatallow the trade of more resilient taxa and restrict trade in species sensitive to hunting

Ancient fires enhance Amazon forest drought resistance

This is the final version. Available on open access from Frontiers Media via the DOI in this recordData availability statement: The datasets presented in this article are not readily available but the raw data supporting the conclusions of this article will be available under reasonable request to the authors. Requests to access the datasets should be directed to TF, [email protected] and fire reduce productivity and increase tree mortality in tropical forests. Fires also produce pyrogenic carbon (PyC), which persists in situ for centuries to millennia, and represents a legacy of past fires, potentially improving soil fertility and water holding capacity and selecting for the survival and recruitment of certain tree life-history (or successional) strategies. We investigated whether PyC is correlated with physicochemical soil properties, wood density, aboveground carbon (AGC) dynamics and forest resistance to severe drought. To achieve our aim, we used an Amazon-wide, long-term plot network, in forests without known recent fires, integrating site-specific measures of forest dynamics, soil properties and a unique soil PyC concentration database. We found that forests with higher concentrations of soil PyC had both higher soil fertility and lower wood density. Soil PyC was not associated with AGC dynamics in non-drought years. However, during extreme drought events (10% driest years), forests with higher concentrations of soil PyC experienced lower reductions in AGC gains (woody growth and recruitment), with this drought-immunizing effect increasing with drought severity. Forests with a legacy of ancient fires are therefore more likely to continue to grow and recruit under increased drought severity. Forests with high soil PyC concentrations (third quartile) had 3.8% greater AGC gains under mean drought, but 33.7% greater under the most extreme drought than forests with low soil PyC concentrations (first quartile), offsetting losses of up to 0.68 Mg C ha–1yr–1 of AGC under extreme drought events. This suggests that ancient fires have legacy effects on current forest dynamics, by altering soil fertility and favoring tree species capable of continued growth and recruitment during droughts. Therefore, mature forest that experienced fires centuries or millennia ago may have greater resistance to current short-term droughts.Coordination of Improvement of Personnel in Higher Education, Brazil (CAPES)Natural Environment Research Council (NERC)FAPESPRoyal SocietyNational Council for Science and Technology Development of Brazil (CNPq

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

BACKGROUND: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. PATIENTS AND METHODS: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8\u2009mg/kg loading dose, then 6\u2009mg/kg every 3\u2009weeks (q3w)] and pertuzumab (840\u2009mg loading dose, then 420\u2009mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). RESULTS: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54\u2009years; 29% had received prior trastuzumab. Median treatment duration was 16\u2009months for pertuzumab and trastuzumab and 4\u2009months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months' median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1\u2009months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). CONCLUSIONS: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile. CLINICALTRIALS.GOV: NCT01572038

A Search for Photons with Energies Above 2X10(17) eV Using Hybrid Data from the Low-Energy Extensions of the Pierre Auger Observatory

Ultra-high-energy photons with energies exceeding 10(17) eV offer a wealth of connections to different aspects of cosmic-ray astrophysics as well as to gamma-ray and neutrino astronomy. The recent observations of photons with energies in the 10(15) eV range further motivate searches for even higher-energy photons. In this paper, we present a search for photons with energies exceeding 2 x 10(17) eV using about 5.5 yr of hybrid data from the low-energy extensions of the Pierre Auger Observatory. The upper limits on the integral photon flux derived here are the most stringent ones to date in the energy region between 10(17) and 10(18) eV